ClinicalTrials.gg
CompletedNCT01417156Updated Mar 6, 2017Results posted

Safety and PK Study of BIBF 1120 in Japanese Patients With IPF: Follow up Study From 1199.31(NCT01136174)

A Phase 2 interventional study of Nintedanib and Pirfenidoneone in Pulmonary Fibrosis, sponsored by Boehringer Ingelheim. Completed at 4 sites in Japan. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2017-03-06.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Pulmonary Fibrosis with a site in Japan — 2 open to participants now, 4 under way, 3 of them phase 3. Pulmonary Fibrosis · Japan.

Enrollment
10th of 10
20 · median 459
Started
2011
with 2 others
Phase 2
4 of 11
none open now
Registered
3rd of 11
by date
Lead sponsor
3 of 11
Boehringer Ingelheim

Among the 11 studies in Pulmonary Fibrosis with a site in Japan, this one is the 10th largest by enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2011, is one of 4 in phase 2, and was the 3rd registered.

Pulmonary Fibrosis

342 studies on the registry are indexed under Pulmonary Fibrosis; 98 are open to participants now.

Browse Pulmonary Fibrosis studies →

Open to participants now

2 of the 11 studies in Pulmonary Fibrosis with a site in Japan are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 71 Pulmonary Fibrosis studies recruiting now, 41 (58%) set no upper age limit and 4 (6%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Pulmonary Fibrosis with a site in Japan, or all of them as a file.
02

Study summary

Primary objective of this study is to investigate the long-term tolerability and safety profile of BIBF 1120 on top of pirfenidone treatment in patients with Idiopathic Pulmonary Fibrosis who have completed a prior clinical trial of BIBF 1120 (1199.31).

Secondary objectives are to assess effects on some efficacy criteria during long term treatment with BIBF 1120 on top of pirfenidone.

03

Conditions studied

  • Pulmonary Fibrosis

Browse trials for

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written consistent with Good Clinical Practice (GCP) signed prior to entry into the study
  2. Completion of 1199.31 study and still under treatment with pirfenidone at a stable dose

Exclusion criteria

Exclusion criteria:

  1. Any disease that may interfere with testing procedures or in judgement of investigator may interfere with trial participation or may put the patient at risk when participating in this trial. Reconsider carefully all exclusion criteria of trial 1199.31. However, patients may qualify for participation even though they meet the exclusion criteria (for 1199.31), if the investigators benefit-risk assessment remains favorable.
  2. Any other therapy received within 8 weeks before visit 1.
  3. For female: Pregnant women or women who are breast feeding or of child bearing potential not using a highly effective method of for both at least 4 weeks prior to enrolment and 10 weeks after last study drug intake.

    For male: Sexually active males not committing to using condoms both during the course of the study and ten weeks after last study drug intake (except if their partner is not of ).

  4. Known or suspected active alcohol or drug abuse.
  5. Patients who require full-dose therapeutic anticoagulation (e.g. vitamin K antagonists, heparin), except low dose heparin and/or heparin flash as needed for maintenance of an indwelling intravenous device. As an example, prophylactic use of heparin, e.g. enoxaparin 2000 International unit (I.U.) subcutaneously (s.c.) per day, should be allowed.
  6. Patients who require full-dose antiplatelet (e.g. acetyl salicylic acid, clopidogrel) therapy. As an example, chronic low-dose acetyl salicylic acid, below or equal to 100 mg per day, should be allowed.
  7. Patient not compliant in previous trial, with trial medication or trial visits.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    All patients

    Drug: Nintedanib · Drug: Pirfenidoneone

Interventions

  • 150 mg bid

  • DrugPirfenidoneone

    Existing treatment

06

What researchers measure

Primary outcomes

  1. Incidence of Overall Adverse Events

    Incidence (Number of patients) of Adverse events (AEs) over the course of treatment period including serious adverse events (SAEs), AEs leading to discontinuation of study medication, and fatal AEs.

    Time frame: First drug administration until end of treatment, up to 5 years

Secondary outcomes

  1. Annual Rate of Decline in Forced Vital Capacity (FVC).

    The adjusted annual rate of decline in Forced Vital Capacity (FVC). The means presents actually the adjusted rate based on a random coefficient regression with fixed effects for gender, age, height and random effect of patient specific intercept and time. Within-patient errors are modelled by an Unstructured variance-covariance matrix. Inter-individual variability is modelled by a Variance-Components variance-covariance matrix. The result for Annual rate of decline (ROD) in FVC should be interpreted with caution and along with descriptive statistics, because inferences used for this analysis might not be valid as suggested by skewed distribution of the data.

    Time frame: Baseline and every 8 weeks after drug administration until end of treatment, up to 5 years

  2. Annual Rate of Decline in Haemoglobin (Hb) Corrected Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)

    Adjusted annual rate of decline in Hb corrected DLCO. The means presents actually adjusted rate based on random coefficient regression with fixed effects for gender, age, height \& random effect of patient specific intercept \& time. Within-patient errors are modelled by Unstructured variance-covariance matrix.Inter-individual variability is modelled by a variance-Components variance-covariance matrix. mmHg: millimeters of mercury

    Time frame: Baseline & every 8 weeks after drug administration until end of treatment, up to 5 years

  3. Acute Exacerbations of IPF: Risk (Incidence Rate) of Acute Exacerbations of IPF.

    The risk (incidence rate calculated as number of patients with at least 1 exacerbation, divided by the total time at risk ×100) of acute exacerbation of IPF.

    Time frame: First drug administration until end of treatment, up to 5 years

  4. Percentage of Patient With First Occurrence of Acute Exacerbations of Idiopathic Pulmonary Fibrosis (IPF) Until Week 234.

    The percentage of patient having first acute exacerbation of Idiopathic Pulmonary Fibrosis (IPF) based on investigator reported adverse events until week 234.

    Time frame: Week 234

07

Results

Posted Mar 6, 2017
Limitations and caveats
Annual ROD in FVC results to be interpreted with caution \& along with descriptive statistics as inferences used might not be valid as suggested by skewed distribution of data thus Absolute Change from baseline in FVC over time has been defined.

Participant flow

Participant flow — Overall Study
MilestoneNintedanib
Started20
Completed6
Not completed14
Withdrew: Adverse event12
Withdrew: Protocol violation2

Outcome measures

PrimaryIncidence of Overall Adverse Events

Incidence (Number of patients) of Adverse events (AEs) over the course of treatment period including serious adverse events (SAEs), AEs leading to discontinuation of study medication, and fatal AEs.

Time frame:
First drug administration until end of treatment, up to 5 years
Reported as:
Number · participants
Incidence of Overall Adverse Events
participantsNintedanib
AEs leading to discontinuation of trial drug12
Fatal8
Severe AEs11
SecondaryAnnual Rate of Decline in Forced Vital Capacity (FVC).

The adjusted annual rate of decline in Forced Vital Capacity (FVC). The means presents actually the adjusted rate based on a random coefficient regression with fixed effects for gender, age, height and random effect of patient specific intercept and time. Within-patient errors are modelled by an Unstructured variance-covariance matrix. Inter-individual variability is modelled by a Variance-Components variance-covariance matrix. The result for Annual rate of decline (ROD) in FVC should be interpreted with caution and along with descriptive statistics, because inferences used for this analysis might not be valid as suggested by skewed distribution of the data.

Time frame:
Baseline and every 8 weeks after drug administration until end of treatment, up to 5 years
Reported as:
Least squares mean · (mililitre (mL)/year)
Annual Rate of Decline in Forced Vital Capacity (FVC).
(mililitre (mL)/year)Nintedanib
Annual Rate of Decline in Forced Vital Capacity (FVC).-233.3 ± 72.59
SecondaryAnnual Rate of Decline in Haemoglobin (Hb) Corrected Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)

Adjusted annual rate of decline in Hb corrected DLCO. The means presents actually adjusted rate based on random coefficient regression with fixed effects for gender, age, height \& random effect of patient specific intercept \& time. Within-patient errors are modelled by Unstructured variance-covariance matrix.Inter-individual variability is modelled by a variance-Components variance-covariance matrix. mmHg: millimeters of mercury

Time frame:
Baseline & every 8 weeks after drug administration until end of treatment, up to 5 years
Reported as:
Mean · mL/Minute(min)/mmHg per year
Annual Rate of Decline in Haemoglobin (Hb) Corrected Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)
mL/Minute(min)/mmHg per yearNintedanib
Annual Rate of Decline in Haemoglobin (Hb) Corrected Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)-1.3 ± 0.26
SecondaryAcute Exacerbations of IPF: Risk (Incidence Rate) of Acute Exacerbations of IPF.

The risk (incidence rate calculated as number of patients with at least 1 exacerbation, divided by the total time at risk ×100) of acute exacerbation of IPF.

Time frame:
First drug administration until end of treatment, up to 5 years
Reported as:
Number · patients per 100 patient-year
Acute Exacerbations of IPF: Risk (Incidence Rate) of Acute Exacerbations of IPF.
patients per 100 patient-yearNintedanib
Acute Exacerbations of IPF: Risk (Incidence Rate) of Acute Exacerbations of IPF.19.2 (8.29 to 37.82)
SecondaryPercentage of Patient With First Occurrence of Acute Exacerbations of Idiopathic Pulmonary Fibrosis (IPF) Until Week 234.

The percentage of patient having first acute exacerbation of Idiopathic Pulmonary Fibrosis (IPF) based on investigator reported adverse events until week 234.

Time frame:
Week 234
Reported as:
Number · percentage of participants
Percentage of Patient With First Occurrence of Acute Exacerbations of Idiopathic Pulmonary Fibrosis (IPF) Until Week 234.
percentage of participantsNintedanib
Failure (Week 234)40.0
Censored (Week 234)60.0

Adverse events

Collected over First drug administration until end of treatment, up to 5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nintedanib—16/20 (80%)19/20 (95%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventNintedanib
Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders13/20
Dyspnoea exertionalRespiratory, thoracic and mediastinal disorders4/20
CholecystitisHepatobiliary disorders2/20
PneumoniaInfections and infestations2/20
Respiratory tract infectionInfections and infestations2/20
Decreased appetiteMetabolism and nutrition disorders2/20
PneumothoraxRespiratory, thoracic and mediastinal disorders2/20
Deep vein thrombosisVascular disorders2/20
Acute myocardial infarctionCardiac disorders1/20
Right ventricular failureCardiac disorders1/20
Most frequent other events
Showing 10 of 35
Most frequent other events
EventNintedanib
DiarrhoeaGastrointestinal disorders13/20
NauseaGastrointestinal disorders12/20
ConstipationGastrointestinal disorders8/20
NasopharyngitisInfections and infestations7/20
Decreased appetiteMetabolism and nutrition disorders7/20
HypertensionVascular disorders6/20
VomitingGastrointestinal disorders5/20
Weight decreasedInvestigations5/20
Abdominal painGastrointestinal disorders4/20
InsomniaPsychiatric disorders4/20

Baseline characteristics

Treated set (TS): This analysis set included all patients who were given study medication and were documented to have taken at least one dose of the trial medication.

Age, Continuous
Age, Continuous(Years)Nintedanib
Mean65.8 ± 9.5
Gender
Gender(Participants)Nintedanib
Female6
Male14
08

Study locations

4 sites
  • Boehringer Ingelheim Investigational Site
    Himeji, Hyogo, Japan
  • Boehringer Ingelheim Investigational Site
    Sakai, Osaka, Japan
  • Boehringer Ingelheim Investigational Site
    Seto, Aichi, Japan
  • Boehringer Ingelheim Investigational Site
    Yokohama, Kanagawa, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Oct 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2011
First posted
Aug 16, 2011
Start
Sep 2011
Primary completionActual
Oct 2015
CompletionActual
Oct 2015
Results first posted
Mar 6, 2017
Last update
Mar 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01417156
Responsible party
Sponsor
First posted
Aug 16, 2011
Start date
Sep 2011
Primary completion
Oct 2015
Completion
Oct 2015
Results posted
Mar 6, 2017
Last update
Mar 6, 2017

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nintedanib

Start the discussion